GLP-1 Peptides & Mast Cell Activation Syndrome (MCAS)

GLP-1 Peptides & Mast Cell Activation Syndrome (MCAS)

GLP-1 Peptides & Mast Cell Activation Syndrome (MCAS):

Emerging Evidence for an Immunometabolic Approach

Mast Cell Activation Syndrome (MCAS) is a complex, multi-system condition characterised by inappropriate mast cell activation and excessive release of inflammatory mediators such as histamine, prostaglandins, and cytokines.

Despite growing awareness, treatment remains largely symptomatic and involves a combination of antihistamines, mast cell stabilisers, and trigger avoidance. For many patients, this is not enough.

Recently, GLP-1 receptor agonists (GLP-1 RAs) which are class of peptides originally developed for type 2 diabetes, have gained attention for their anti-inflammatory and immune-modulating effects, with early evidence suggesting potential relevance in MCAS.

Understanding MCAS as an Immune Dysregulation Disorder

Mast cells play a central role in the immune system. In MCAS, these cells become dysregulated, leading to:

·      Chronic system inflammation

·      Gastrointestinal dysfunction

·      Dermatological symptoms (flushing, urticaria)

·      Neurological effects (brain fog, anxiety)

·      Autonomic instability

The multi-system involvement reflects the widespread distribution of mast cells throughout the body (Afrin, 2016).

GLP-1: Beyond Metabolism

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates glucose metabolism. However, GLP-1 receptors are also expressed in:

  • Immune cells
  • The central nervous system
  • The gastrointestinal tract

This has led to increasing research into GLP-1’s broader physiological roles.

Clinical Observations: GLP-1 Receptor Agonists in MCAS Patients

One of the most compelling early insights into the use of GLP-1 receptor agonists in Mast Cell Activation Syndrome comes from clinical observations shared by Lawrence Afrin, a leading authority in mast cell disorders.

In a case series involving 47 patients with treatment-resistant MCAS, approximately 89% of patients experienced clinically meaningful improvement following treatment with GLP-1 receptor agonists.

Reported improvements included:

  • Reduction in gastrointestinal symptoms such as bloating, pain, and dysmotility
  • Improvements in neurological symptoms, including brain fog and fatigue
  • Decreased frequency and severity of mast cell activation episodes
  • Overall reduction in systemic inflammatory burden

Importantly, these were patients who had not responded adequately to standard therapies, including antihistamines and mast cell stabilisers—highlighting the potential significance of this response rate.

Reference:
Afrin LB et al. Use of GLP-1 receptor agonists in mast cell activation syndrome: case series and clinical observations (2024–2025, emerging data).

Detailed Case Study

One particularly illustrative case from the paper describes a young male patient with long-standing, severe multi-system MCAS beginning in early infancy.

Clinical presentation:

  • Chronic inflammatory symptoms from infancy
  • Recurrent upper respiratory–type inflammatory episodes
  • Migratory tendinitis and spondyloarthropathy
  • Diffuse cutaneous hypersensitivity, cold and heat-induced urticaria, flushing, and diaphoresis
  • Gastrointestinal symptoms including abdominal pain and non-bloody diarrhoea
  • Neuropsychiatric symptoms: anxiety, panic, depression
  • Autonomic dysfunction: labile hypertension and temperature dysregulation

By early adulthood, the patient experienced:

  • Severe chronic fatigue
  • Cognitive dysfunction (“brain fog”)
  • Persistent systemic inflammation despite treatment

Prior treatment history:

The patient underwent extensive therapeutic trials, including:

  • H1 and H2 antihistamines
  • Montelukast
  • Ketotifen and cromolyn
  • Omalizumab
  • NSAIDs, cannabinoids, and nutraceutical interventions

Despite partial responses to some therapies, symptoms remained debilitating and refractory overall.

GLP-1 intervention:

At age 24, semaglutide was initiated off-label at 0.25 mg weekly.

Observed response:

  • Within hours:
    • Normalisation of appetite
    • Stabilisation of blood pressure
  • Over subsequent weeks and months:
    • Marked reduction in fatigue and cognitive dysfunction
    • Significant improvement in systemic inflammatory symptoms
    • Decreased mast cell-related reactivity

Dose escalation (up to 0.75 mg, later 2.0 mg) resulted in further incremental improvements, with:

  • Sustained symptom control
  • No reported adverse effects
  • Reported improvement in mitochondrial function testing

Additional outcome:

The patient experienced approximately 30 pounds of weight loss, which clinical assessment suggested was largely due to reduction in chronic inflammatory oedema, rather than significant adipose tissue loss.

Reference

·       Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR.
Utility of Glucagon-Like Peptide-1 Receptor Agonists in Mast Cell Activation Syndrome.
(2024–2025, clinical case series).

In a condition defined by complexity, GLP-1 receptor agonists offer a compelling, system-wide approach that may extend beyond traditional symptom management. That said, the evidence base is still emerging, and potential risks including nausea, delayed gastric emptying, and differing patient tolerability, must be carefully considered. This article is designed to inform, not to diagnose or treat, and individuals should always seek guidance from a healthcare professional before exploring any new therapy.